MNMichael B. Nelappana

Michael B. Nelappana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael B. Nelappana has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Role of the Receptor for Advanced Glycation End-Products in Cancer: Evidence from a Systematic Review and Meta-Analysis

    by Michael B. Nelappana, Pawel Wityk, Catherine C. Applegate, Goodluck Okoro, Leszek B Kalinowski, Iwona T. Dobrucki, Lawrence W. Dobrucki

    The Receptor for Advanced Glycation End-products (RAGE) has been implicated in driving cancer growth, aggression, and metastasis through the fueling of chronic inflammation in the tumor microenvironment. This systematic review and meta-analysis summarize and analyze current clinical and preclinical data to provide insight into the relationship between RAGE and cancer, cancer grade, metastasis, patient survival, and cellular processes. A multi-database search was performed to identify original clinical and preclinical research studies examining RAGE expression in cancer. After screening and review, 53 clinical and 233 preclinical studies were included. Associations of RAGE with clinical cancer outcomes were estimated using odds ratio (OR) and associated 95% confidence intervals (CI). The meta-analysis found that RAGE expression was highly correlated with cancerous tissue when compared to controls; high-grade tumors; regional lymph node invasion; and was somewhat negatively associated with patient survival. In addition, meta-analysis estimates of preclinical studies found positive associations between RAGE expression/activation and cancer growth, metastatic potential, evasion of apoptosis, and activated NF-κB expression. This systematic review and meta-analysis is the first comprehensive study through which both preclinical and clinical research in all available cancer types are assessed for correlations with RAGE expression and activation, demonstrating that RAGE does indeed play a significant role in cancer progression and that further research is warranted.


  • Open Access

    Enhancing radiomic feature selection in PET-based heterogeneity analysis through tumor-volume-weighted normalization

    by Goodluck Okoro, Catherine C. Applegate, Michael B. Nelappana, Elaine A. Nielsen, Iwona T. Dobrucki, Lawrence W. Dobrucki


  • Open Access

    Cutting-edge approaches to diagnosing and treating limb ischemia in peripheral arterial disease

    by Goodluck Okoro, Fortune K Owunnah, Catherine C Applegate, Michael B Nelappana, Iwona T Dobrucki, Lawrence W Dobrucki

    Peripheral arterial disease (PAD) is a common circulatory condition that leads to reduced blood flow to the limbs, often resulting in limb ischemia which can severely impact a patient’s quality of life and increase the risk of amputation. Early diagnosis and timely intervention are critical in managing PAD-associated limb ischemia. This review provides a comprehensive overview of the latest diagnostic and therapeutic approaches for PAD and limb ischemia. We explored both non-invasive and invasive diagnostic techniques including ankle–brachial index, duplex ultrasonography, magnetic resonance angiography, computed tomography angiography and emerging technologies like molecular imaging and near-infrared spectroscopy. Therapeutic strategies discussed include pharmacological treatments such as antiplatelet agents and statins, endovascular interventions like angioplasty and stenting as well as advanced options such as gene and stem cell therapies. Emerging treatments including non-thermal plasma and extracellular vesicle therapy are also highlighted for their regenerative potential. We have also addressed the challenges of current approaches, including diagnostic limitations, barriers to new therapies and cost considerations aimed at improving outcomes for PAD patients.


  • Open Access

    Receptor for advanced glycation end‐products: Biological significance and imaging applications

    by Iwona T. Dobrucki, Angelo Miskalis, Michael Nelappana, Catherine Applegate, Marcin Wozniak, Andrzej Czerwinski, Leszek Kalinowski, Lawrence W. Dobrucki

    The receptor for advanced glycation end‐products (RAGE or AGER) is a transmembrane, immunoglobulin‐like receptor that, due to its multiple isoform structures, binds to a diverse range of endo‐ and exogenous ligands. RAGE activation caused by the ligand binding initiates a cascade of complex pathways associated with producing free radicals, such as reactive nitric oxide and oxygen species, cell proliferation, and immunoinflammatory processes. The involvement of RAGE in the pathogenesis of disorders such as diabetes, inflammation, tumor progression, and endothelial dysfunction is dictated by the accumulation of advanced glycation end‐products (AGEs) at pathologic states leading to sustained RAGE upregulation. The involvement of RAGE and its ligands in numerous pathologies and diseases makes RAGE an interesting target for therapy focused on the modulation of both RAGE expression or activation and the production or exogenous administration of AGEs. Despite the known role that the RAGE/AGE axis plays in multiple disease states, there remains an urgent need to develop noninvasive, molecular imaging approaches that can accurately quantify RAGE levels in vivo that will aid in the validation of RAGE and its ligands as biomarkers and therapeutic targets.This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Diagnostic Tools > Biosensing


  • Open Access

    RAGE as a Novel Biomarker for Prostate Cancer: A Systematic Review and Meta-Analysis

    by Catherine C. Applegate, Michael B. Nelappana, Elaine A. Nielsen, Leszek Kalinowski, Iwona T. Dobrucki, Lawrence W. Dobrucki

    The receptor for advanced glycation end-products (RAGE) has been implicated in driving prostate cancer (PCa) growth, aggression, and metastasis through the fueling of chronic inflammation in the tumor microenvironment. This systematic review and meta-analysis summarizes and analyzes the current clinical and preclinical data to provide insight into the relationships among RAGE levels and PCa, cancer grade, and molecular effects. A multi-database search was used to identify original clinical and preclinical research articles examining RAGE expression in PCa. After screening and review, nine clinical and six preclinical articles were included. The associations of RAGE differentiating benign prostate hyperplasia (BPH) or normal prostate from PCa and between tumor grades were estimated using odds ratios (ORs) and associated 95% confidence intervals (CI). Pooled estimates were calculated using random-effect models due to study heterogeneity. The clinical meta-analysis found that RAGE expression was highly likely to be increased in PCa when compared to BPH or normal prostate (OR: 11.3; 95% CI: 4.4–29.1) and that RAGE was overexpressed in high-grade PCa when compared to low-grade PCa (OR: 2.5; 95% CI: 1.8–3.4). In addition, meta-analysis estimates of preclinical studies performed by albatross plot generation found robustly positive associations among RAGE expression/activation and PCa growth and metastatic potential. This review demonstrates that RAGE expression is strongly tied to PCa progression and can serve as an effective diagnostic target to differentiate between healthy prostate, low-grade PCa, and high-grade PCa, with potential theragnostic applications.


  • Open Access

    Ensemble and single-particle level fluorescent fine-tuning of carbon dots via positional changes of amines toward “supervised” oral microbiome sensing

    by Fatemeh Ostadhossein, Parikshit Moitra, Maha Alafeef, Dinabandhu Sar, Shannon D’souza, Lily F. Benig, Michael Nelappana, Xuedong Huang, Julio Soares, Kai Zhang, et al.

    SignificanceCarbon dots (CDs) have attracted a host of research interest in recent years mainly due to their unique photoluminescence (PL) properties that make them applicable in various biomedical areas, such as imaging and image-guided therapy. However, the real mechanism underneath the PL is a subject of wide controversy and can be investigated from various angles.AimOur work investigates the effect of the isomeric nitrogen position as the precursor in the synthesis of CDs by shedding light on their photophysical properties on the single particles and ensemble level.ApproachTo this end, we adopted five isomers of diaminopyridine (DAP) and urea as the precursors and obtained CDs during a hydrothermal process. The various photophysical properties were further investigated in depth by mass spectroscopy. CD molecular frontier orbital analyses aided us in justifying the fluorescence emission profile on the bulk level as well as the charge transfer processes. As a result of the varying fluorescent responses, we indicate that these particles can be utilized for machine learning (ML)-driven sensitive detection of oral microbiota. The sensing results were further supported by density functional theoretical calculations and docking studies.ResultsThe generating isomers have a significant effect on the overall photophysical properties at the bulk/ensembled level. On the single-particle level, although some of the photophysical properties such as average intensity remained the same, the overall differences in brightness, photo-blinking frequency, and bleaching time between the five samples were conceived. The various photophysical properties could be explained based on the different chromophores formed during the synthesis. Overall, an array of CDs was demonstrated herein to achieve ∼100 % separation efficacy in segregating a mixed oral microbiome culture in a rapid (<0.5 h), high-throughput manner with superior accuracy.ConclusionsWe have indicated that the PL properties of CDs can be regulated by the precursors’ isomeric position of nitrogen. We emancipated this difference in a rapid method relying on ML algorithms to segregate the dental bacterial species as biosensors.


  • Hitchhiking probiotic vectors to deliver ultra-small hafnia nanoparticles for ‘Color’ gastrointestinal tract photon counting X-ray imaging

    by Fatemeh Ostadhossein, Parikshit Moitra, Nivetha Gunaseelan, Michael Nelappana, Chiara Lowe, Mahdieh Moghiseh, Anthony Butler, Niels de Ruiter, Harish Mandalika, Indu Tripathi, et al.

    Gastrointestinal (GI) tract is one of the hard-to-reach target tissues for the delivery of contrast agents and drugs mediated by nanoparticles due to its harsh environment. Herein, we overcame this barrier by designing orally ingestible probiotic vectors for ‘hitchhiking’ ultrasmall hafnia (HfO2) (∼1–2 nm) nanoparticles. The minute-made synthesis of these nanoparticles is accomplished through a simple reduction reaction. These nanoparticles were incubated with probiotic bacteria with potential health benefits and were non-specifically taken up due to their small size. Subsequently, the bacteria were lyophilized and packed into a capsule to be administered orally as the radiopaque contrast agents for delineating the GI features. These nano-bio-hybrid entities could successfully be utilized as contrast agents in vivo in the conventional and multispectral computed tomography (CT). We demonstrated in ‘color’ the accumulated nanoparticles using advanced detectors of the photon counting CT. The enhanced nano-bio-interfacing capability achieved here can circumvent traditional nanoparticle solubility and delivery problems while offering a patient friendly approach for GI imaging to replace the currently practiced barium meal.